RESEARCH

Pancreas deficiency modifies bone development in the ovine fetus near term

Stuart A Lanham¹, Dominique Blache², Richard O C Oreffo¹, Abigail L Fowden³ and Alison J Forhead^{3,4}

- ¹Bone and Joint Research Group, Centre for Human Development, Stem Cells and Regeneration, School of Medicine, University of Southampton, Southampton, UK
- ²School of Agriculture and Environment, University of Western Australia, Crawley, Australia
- ³Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, UK
- ⁴Department of Biological and Medical Sciences, Oxford Brookes University, Oxford, UK

Correspondence should be addressed to A J Forhead: ajf1005@cam.ac.uk

Abstract

Hormones have an important role in the regulation of fetal growth and development, especially in response to nutrient availability in utero. Using micro-CT and an electromagnetic three-point bend test, this study examined the effect of pancreas removal at 0.8 fraction of gestation on the developing bone structure and mechanical strength in fetal sheep. When fetuses were studied at 10 and 25 days after surgery, pancreatectomy caused hypoinsulinaemia, hyperglycaemia and growth retardation which was associated with low plasma concentrations of leptin and a marker of osteoclast activity and collagen degradation. In pancreatectomized fetuses compared to control fetuses, limb lengths were shorter, and trabecular (Tb) bone in the metatarsi showed greater bone volume fraction, Tb thickness, degree of anisotropy and porosity, and lower fractional bone surface area and Tb spacing. Mechanical strength testing showed that pancreas deficiency was associated with increased stiffness and a greater maximal weight load at fracture in a subset of fetuses studied near term. Overall, pancreas deficiency in utero slowed the growth of the fetal skeleton and adapted the developing bone to generate a more compact and connected structure. Maintenance of bone strength in growth-retarded limbs is especially important in a precocial species in preparation for skeletal loading and locomotion at birth.

Key Words

- ▶ fetus
- pancreas
- ▶ insulin
- glucose
- ▶ leptin
- micro-computed tomography
- ▶ bone structure
- metatarsal
- skeleton

Journal of Endocrinology (2021) **252**, 71–80

Introduction

Growth and development of long bones during late gestation are important for the normal functioning of the neonatal skeleton, especially in precocial species like sheep that stand and are mobile from birth. In normal and adverse intrauterine conditions, a number of hormones are known to regulate skeletal growth and development *in utero* to optimize the size, structure and mechanical strength of bone (Agrogiannis *et al.* 2014, Kovacs 2014). The majority of studies have focused, however, on the endocrine control of bone development in altricial species where the skeleton

is not required for weight-bearing or locomotion until later in postnatal life.

Insulin is a key growth hormone in the fetus. It is secreted by the fetal pancreas in response to changes in nutrient availability and coordinates appropriate growth and development of fetal tissues, including the skeleton (Fowden 1992, Sferruzzi-Perri et al. 2013). A range of experimental animal models have demonstrated that suboptimal intrauterine conditions, such as undernutrition and/or hypoxia, are associated with



impaired insulin secretion and skeletal growth retardation and have investigated further the role of insulin in the control of fetal growth in large animals (Fowden 1993, Boehmer *et al.* 2017). In fetal sheep, surgical removal of the pancreas or treatment with streptozocin to damage pancreatic β -cells causes growth retardation of the axial and appendicular skeleton, delayed ossification of limb bones as assessed by radiography, proportionate growth restriction of organs and sparing of the growth of the brain (Brinsmead & Thorburn 1982, Fowden *et al.* 1989, Philipps *et al.* 1991). In these studies, the percentage reduction in body weight was greater than the percentage reduction in body and limb lengths. The findings suggest that there are tissue-specific effects, and relative preservation of skeletal growth, following insulin deficiency in fetal sheep.

In postnatal life, insulin contributes to the regulation of bone formation and remodelling (Pramojanee *et al.* 2014), although relatively less is known about its actions on the skeleton before birth, especially in precocial offspring. Studies *in vitro* have demonstrated that insulin stimulates collagen and DNA synthesis and bone matrix formation in rat fetuses near term and proliferation of chondrocytes isolated from ovine fetal growth plates (Hock *et al.* 1988, Hill & de Sousa 1990). To date, however, the role of insulin in determining the structural and mechanical properties of developing bone near term has not been investigated in detail in large animals.

This study aims to investigate the effects of hypoinsulinaemia *in utero*, induced by removal of the fetal pancreas, on aspects of the structure and mechanical strength of bone in the sheep fetus using micro-CT and an electromagnetic three-point bend test. It tests the hypothesis that pancreas deficiency will impair the structural organization and development of fetal bone with consequences for the growth of the fetal skeleton and its weight-bearing capacity. Pancreas deficient and control fetuses were examined at two ages during late gestation, at the start and during the plateau phase of skeletal growth observed shortly before birth in sheep (Fowden *et al.* 1996).

Methods

Animals

This study used the sheep as an example of a precocial species where the skeleton is weight-loaded and required for motility at birth and where circulating insulin concentrations in the fetus can be manipulated experimentally over a period

of late gestation by pancreatectomy. This large animal model of insulin deficiency *in utero* has been characterized previously, in terms of aspects of fetal growth and metabolism (Fowden 1993, Fowden & Forhead 2012).

A total of 24 Welsh Mountain sheep fetuses of known gestational age were used in the study. There were 13 singleton and 11 twin fetuses distributed evenly across 4 groups (sham and pancreatectomized (PX), at 2 gestational ages: 129 and 144 days of gestation, where term is 145 ± 2 days; Table 1). In four ewes with a twin pregnancy, the pancreas was removed in one fetus while the other acted as the sham-operated control; in three twin-bearing ewes, only one of the fetuses was included in the study, in either sham or PX groups. No siblings were included in the same treatment group. The pregnant ewes were housed individually and maintained on 200 g/ day concentrates with free access to hay, water and a saltlick block. Food, but not water, was withheld for 18-24 h before surgery. All surgical and experimental procedures were carried out in accordance with the UK Animals (Scientific Procedures) Act 1986 and approved by the animal ethics committee at the University of Cambridge.

Surgical procedures

The pregnant ewes were fasted, with access to water, for 18-24 h before surgery. Surgical operations were carried out under general anaesthesia (1.5% halothane in O_2 – N_2O) with positive pressure ventilation. Between 115 and 120 days of gestation, fetuses were either pancreatectomized (PX, n=11) or sham-operated (sham, n=13), where the pancreas was exposed but not removed (Fowden & Comline 1984). Catheters were inserted into the fetal aorta and vena cava and the maternal aorta, via the femoral vessels and exteriorized through the flank of the ewe and secured in a bag sutured to the skin, as described previously (Comline & Silver 1972).

At surgery, all fetuses were administered 100 mg ampicillin i.v. (Penbritin; Beecham Animal Health, Brentford, UK) and 2 mg gentamicin i.v. (Frangen-100; Biovet, Mullingar, Ireland). The ewes were given antibiotics i.m. (procaine penicillin, Depocillin; Mycofarm, Cambridge, UK) on the day of surgery and daily for the next 3 days. All vascular catheters were flushed daily with heparinized saline solution (100 IU heparin in 0.9% (w/v) saline) from the day after surgery. During the study, daily blood samples collected from these catheters were used to monitor fetal wellbeing by measuring blood gases and pH.



Table 1 Mean (± s.E.M.) measurements of bodyweight, crown-rump and limb lengths, and plasma hormone and metabolite concentrations, in sham and PX sheep fetuses at 129 and 144 days of gestation.

| Number of fetuses $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | Gestational age (days) | 129 | | 144 | | Two-way ANOVA analyses | | |
|--|-----------------------------|-----------------|-----------------------------|-------------------------|------------------------------|------------------------|------------------|-----------------|
| Body weight (kg) 2.71 ± 0.18 2.41 ± 0.11 3.74 ± 0.25 a 3.17 ± 0.23 a $P < 0.05$ $P < 0.001$ NS Crown-rump length (cm) 42.6 ± 1.2 42.2 ± 1.1 50.8 ± 1.7 a 47.2 ± 1.8 a NS $P < 0.001$ NS Metatarsus/phalanges (cm) 15.6 ± 0.4 14.8 ± 0.3 17.8 ± 0.8 a 16.0 ± 0.6 b $P < 0.01$ $P < 0.001$ NS Tibia (cm) 13.4 ± 0.4 13.0 ± 0.3 15.8 ± 0.4 a 13.6 ± 0.4 b $P < 0.005$ $P < 0.001$ $P < 0.001$ NS Total fore-limb length (cm) 31.1 ± 0.4 11.0 ± 0.5 13.2 ± 0.7 a 11.8 ± 0.4 NS $P < 0.005$ NS Total fore-limb length (cm) 33.1 ± 0.8 31.3 ± 1.0 36.4 ± 1.0 a 34.4 ± 1.5 NS $P < 0.01$ NS Metacarpus/phalanges (cm) 13.2 ± 0.3 12.2 ± 0.3 b 14.4 ± 0.2 a 13.2 ± 0.6 b $P < 0.01$ $P < 0.005$ NS Radius (cm) 10.8 ± 0.3 10.3 ± 0.4 12.0 ± 0.3 a 11.2 ± 0.5 NS $P < 0.05$ NS NS Humerus (cm) 9.1 ± 0.3 8.8 ± 0.4 10.0 ± 0.5 10.0 ± 0.5 NS $P < 0.005$ NS NS Cortisol (ng/mL) 0.30 ± 0.06 0.05 ± 0.01 b 0.34 ± 0.17 0.04 ± 0.01 b $P < 0.005$ NS NS Cortisol (ng/mL) 11.6 ± 1.8 12.2 ± 2.1 76.3 ± 17.2 a 36.2 ± 7.1 a NS $P < 0.001$ NS NS Cortisol (ng/mL) 0.18 ± 0.02 0.16 ± 0.02 0.55 ± 0.16 a 0.30 ± 0.03 a NS $P < 0.001$ NS NS COTK (ng/mL) 0.76 ± 0.04 0.68 ± 0.07 0.99 ± 0.24 0.43 ± 0.06 b $P < 0.005$ NS NS NS COTK (ng/mL) 0.76 ± 0.04 0.68 ± 0.07 0.99 ± 0.24 0.43 ± 0.06 b $P < 0.005$ NS NS NS OSteocalcin (ng/mL) 12.2 ± 1.2 12.9 ± 0.3 11.9 ± 1.5 13.1 ± 0.8 NS NS | Treatment | Sham | PX | Sham | PX | Treatment | Gestational age | Interaction |
| Crown-rump length (cm) 42.6 ± 1.2 42.2 ± 1.1 50.8 ± 1.7^a 47.2 ± 1.8^a NS $P < 0.001$ NS Total hind-limb length (cm) 40.4 ± 1.1 38.8 ± 1.0 46.8 ± 1.5^a 41.4 ± 1.3^b $P < 0.01$ $P < 0.001$ NS Metatarsus/phalanges (cm) 15.6 ± 0.4 14.8 ± 0.3 17.8 ± 0.8^a 16.0 ± 0.6^b $P < 0.01$ $P < 0.001$ NS Tibia (cm) 13.4 ± 0.4 13.0 ± 0.3 15.8 ± 0.4^a 13.6 ± 0.4^b $P < 0.005$ $P < 0.001$ $P < 0.005$ Femur (cm) 11.4 ± 0.4 11.0 ± 0.5 13.2 ± 0.7^a 11.8 ± 0.4 NS $P < 0.05$ NS Total fore-limb length (cm) 33.1 ± 0.8 31.3 ± 1.0 36.4 ± 1.0^a 34.4 ± 1.5 NS $P < 0.01$ NS Metacarpus/phalanges (cm) 13.2 ± 0.3 12.2 ± 0.3^b 14.4 ± 0.2^a 13.2 ± 0.6^b $P < 0.01$ $P < 0.005$ NS Radius (cm) 10.8 ± 0.3 10.3 ± 0.4 10.0 ± 0.3^a 11.2 ± 0.5 NS $P < 0.05$ NS Humerus (cm) 9.1 ± 0.3 8.8 ± 0.4 10.0 ± 0.5 10.0 ± 0.5 NS $P < 0.05$ NS Oction (ng/mL) 0.30 ± 0.06 0.05 ± 0.01^b 0.34 ± 0.17 0.04 ± 0.01^b $P < 0.005$ NS NS Oction (ng/mL) 0.71 ± 0.08 1.02 ± 0.09 0.73 ± 0.13 1.49 ± 0.32^b $P < 0.005$ NS NS Oction (ng/mL) 0.18 ± 0.02 0.16 ± 0.02 0.55 ± 0.16^a 0.30 ± 0.03^a NS 0.16 ± 0.02 0.16 ± 0.02 0.16 ± 0.02 0.16 ± 0.07 0.11 ± 0.04^b $0.03 + 0.005$ NS NS OCTX (ng/mL) 0.76 ± 0.04 0.68 ± 0.07 0.99 ± 0.24 0.43 ± 0.06^b $P < 0.05$ NS NS OSteocalcin (ng/mL) 0.76 ± 0.04 0.68 ± 0.07 0.99 ± 0.24 0.43 ± 0.06^b $P < 0.05$ NS NS | Number of fetuses | • • | | , , | , , | | | |
| Total hind-limb length (cm) 40.4 ± 1.1 38.8 ± 1.0 46.8 ± 1.5^a 41.4 ± 1.3^b $P < 0.01$ $P < 0.001$ NS Metatarsus/phalanges (cm) 15.6 ± 0.4 14.8 ± 0.3 17.8 ± 0.8^a 16.0 ± 0.6^b $P < 0.01$ $P < 0.001$ NS Tibia (cm) 13.4 ± 0.4 13.0 ± 0.3 15.8 ± 0.4^a 13.6 ± 0.4^b $P < 0.005$ $P < 0.001$ $P < 0.00$ Pemur (cm) 11.4 ± 0.4 11.0 ± 0.5 13.2 ± 0.7^a 11.8 ± 0.4 NS $P < 0.05$ NS Total fore-limb length (cm) 33.1 ± 0.8 31.3 ± 1.0 36.4 ± 1.0^a 34.4 ± 1.5 NS $P < 0.01$ NS Metacarpus/phalanges (cm) 13.2 ± 0.3 12.2 ± 0.3^b 14.4 ± 0.2^a 13.2 ± 0.6^b $P < 0.01$ $P < 0.005$ NS Radius (cm) 10.8 ± 0.3 10.3 ± 0.4 12.0 ± 0.3^a 11.2 ± 0.5 NS $P < 0.05$ NS Humerus (cm) 9.1 ± 0.3 8.8 ± 0.4 10.0 ± 0.5 10.0 ± 0.5 NS $P < 0.05$ NS Oction (ng/mL) 0.30 ± 0.06 0.05 ± 0.01^b 0.34 ± 0.17 0.04 ± 0.01^b $P < 0.005$ NS NS Cortisol (ng/mL) 11.6 ± 1.8 12.2 ± 2.1 76.3 ± 17.2^a 36.2 ± 7.1^a NS $P < 0.001$ NS T4 (ng/mL) 87.7 ± 10.9 74.3 ± 8.8 65.5 ± 8.7 43.4 ± 4.6^a NS $P < 0.001$ NS NS CTX (ng/mL) 0.76 ± 0.04 0.68 ± 0.07 0.99 ± 0.24 0.43 ± 0.06^b $P < 0.05$ NS NS NS NS NS NS | Body weight (kg) | 2.71 ± 0.18 | 2.41 ± 0.11 | 3.74 ± 0.25^{a} | 3.17 ± 0.23^{a} | P < 0.05 | <i>P</i> < 0.001 | NS |
| $ \begin{array}{llllllllllllllllllllllllllllllllllll$ | Crown-rump length (cm) | 42.6 ± 1.2 | 42.2 ± 1.1 | 50.8 ± 1.7 ^a | 47.2 ± 1.8^{a} | NS | <i>P</i> < 0.001 | NS |
| Tibia (cm) 13.4 ± 0.4 13.0 ± 0.3 15.8 ± 0.4^a 13.6 ± 0.4^b $P < 0.005$ $P < 0.001$ $P < 0.00$ Femur (cm) 11.4 ± 0.4 11.0 ± 0.5 13.2 ± 0.7^a 11.8 ± 0.4 NS $P < 0.05$ NS Total fore-limb length (cm) 33.1 ± 0.8 31.3 ± 1.0 36.4 ± 1.0^a 34.4 ± 1.5 NS $P < 0.01$ NS Metacarpus/phalanges (cm) 13.2 ± 0.3 12.2 ± 0.3^b 14.4 ± 0.2^a 13.2 ± 0.6^b $P < 0.01$ $P < 0.005$ NS Radius (cm) 10.8 ± 0.3 10.3 ± 0.4 12.0 ± 0.3^a 11.2 ± 0.5 NS $P < 0.05$ NS Humerus (cm) 9.1 ± 0.3 8.8 ± 0.4 10.0 ± 0.5 10.0 ± 0.5 NS $P < 0.05$ NS OS Rollin (ng/mL) 0.30 ± 0.06 0.05 ± 0.01^b 0.34 ± 0.17 0.04 ± 0.01^b $P < 0.005$ NS NS OS Cortisol (ng/mL) 0.71 ± 0.08 1.02 ± 0.09 0.73 ± 0.13 1.49 ± 0.32^b $P < 0.005$ NS NS T4 (ng/mL) 0.16 ± 1.8 12.2 ± 2.1 12.2 ± 1.2 12.2 ± 1.2 12.2 ± 1.2 12.9 ± 0.3 11.9 ± 1.5 13.1 ± 0.8 NS | Total hind-limb length (cm) | 40.4 ± 1.1 | 38.8 ± 1.0 | 46.8 ± 1.5 ^a | 41.4 ± 1.3b | <i>P</i> < 0.01 | <i>P</i> < 0.001 | NS |
| Femur (cm) 11.4 ± 0.4 11.0 ± 0.5 13.2 ± 0.7^a 11.8 ± 0.4 NS $P < 0.05$ NS Total fore-limb length (cm) 33.1 ± 0.8 31.3 ± 1.0 36.4 ± 1.0^a 34.4 ± 1.5 NS $P < 0.01$ NS Metacarpus/phalanges (cm) 13.2 ± 0.3 12.2 ± 0.3^b 14.4 ± 0.2^a 13.2 ± 0.6^b $P < 0.01$ $P < 0.005$ NS Radius (cm) 10.8 ± 0.3 10.3 ± 0.4 12.0 ± 0.3^a 11.2 ± 0.5 NS $P < 0.05$ NS Humerus (cm) 9.1 ± 0.3 8.8 ± 0.4 10.0 ± 0.5 10.0 ± 0.5 NS $P < 0.05$ NS NS Cortisol (ng/mL) 0.71 ± 0.08 1.02 ± 0.09 0.73 ± 0.13 1.49 ± 0.32^b $P < 0.005$ NS NS Cortisol (ng/mL) 11.6 ± 1.8 12.2 ± 2.1 76.3 ± 17.2^a 36.2 ± 7.1^a NS $P < 0.05$ NS T3 (ng/mL) 0.18 ± 0.02 0.16 ± 0.02 0.55 ± 0.16^a 0.30 ± 0.03^a NS $P < 0.001$ NS CTX (ng/mL) 0.76 ± 0.04 0.68 ± 0.07 0.99 ± 0.24 0.43 ± 0.06^b $P < 0.05$ NS | Metatarsus/phalanges (cm) | 15.6 ± 0.4 | 14.8 ± 0.3 | 17.8 ± 0.8^{a} | 16.0 ± 0.6 ^b | P < 0.01 | <i>P</i> < 0.001 | NS |
| Total fore-limb length (cm) 33.1 ± 0.8 31.3 ± 1.0 36.4 ± 1.0^a 34.4 ± 1.5 NS $P < 0.01$ NS Metacarpus/phalanges (cm) 13.2 ± 0.3 12.2 ± 0.3^b 14.4 ± 0.2^a 13.2 ± 0.6^b $P < 0.01$ $P < 0.005$ NS Radius (cm) 10.8 ± 0.3 10.3 ± 0.4 12.0 ± 0.3^a 11.2 ± 0.5 NS $P < 0.05$ NS Humerus (cm) 9.1 ± 0.3 8.8 ± 0.4 10.0 ± 0.5 10.0 ± 0.5 NS $P < 0.05$ NS NS Cortisol (ng/mL) 0.71 ± 0.08 1.02 ± 0.09 0.73 ± 0.13 1.49 ± 0.32^b $P < 0.005$ NS NS Cortisol (ng/mL) 11.6 ± 1.8 12.2 ± 2.1 76.3 ± 17.2^a 36.2 ± 7.1^a NS $P < 0.001$ NS T3 (ng/mL) 0.18 ± 0.02 0.16 ± 0.02 0.55 ± 0.16^a 0.30 ± 0.03^a NS $P < 0.001$ NS CTX (ng/mL) 0.76 ± 0.04 0.68 ± 0.07 0.99 ± 0.24 0.43 ± 0.06^b $P < 0.05$ NS NS NS CTX (ng/mL) 0.76 ± 0.04 0.68 ± 0.07 0.99 ± 0.24 0.43 ± 0.06^b $P < 0.05$ NS NS NS | Tibia (cm) | 13.4 ± 0.4 | 13.0 ± 0.3 | 15.8 ± 0.4^{a} | 13.6 ± 0.4^{b} | P < 0.005 | <i>P</i> < 0.001 | <i>P</i> < 0.05 |
| $\begin{array}{llllllllllllllllllllllllllllllllllll$ | Femur (cm) | 11.4 ± 0.4 | 11.0 ± 0.5 | 13.2 ± 0.7^{a} | 11.8 ± 0.4 | NS | <i>P</i> < 0.05 | NS |
| Radius (cm) 10.8 ± 0.3 10.3 ± 0.4 12.0 ± 0.3^a 11.2 ± 0.5 NS $P < 0.05$ NS Humerus (cm) 9.1 ± 0.3 8.8 ± 0.4 10.0 ± 0.5 10.0 ± 0.5 NS $P < 0.05$ NS NS Insulin (ng/mL) 0.30 ± 0.06 0.05 ± 0.01^b 0.34 ± 0.17 0.04 ± 0.01^b 0.05 NS NS Oction (ng/mL) 0.71 ± 0.08 0.05 ± 0.09 0.73 ± 0.13 0.04 ± 0.01^b 0.05 NS NS NS Cortisol (ng/mL) 0.71 ± 0.08 0.05 ± 0.09 0.73 ± 0.13 0.05 ± 0.09 0.05 ± 0.005 NS NS NS Cortisol (ng/mL) 0.08 ± 0.09 0.09 ± 0.08 0.09 | Total fore-limb length (cm) | 33.1 ± 0.8 | 31.3 ± 1.0 | 36.4 ± 1.0^{a} | 34.4 ± 1.5 | NS | <i>P</i> < 0.01 | NS |
| Humerus (cm) 9.1 ± 0.3 8.8 ± 0.4 10.0 ± 0.5 10.0 ± 0.5 NS $P < 0.05$ NS NS Insulin (ng/mL) 0.30 ± 0.06 0.05 ± 0.01^b 0.34 ± 0.17 0.04 ± 0.01^b $P < 0.005$ NS NS Glucose (mmol/L) 0.71 ± 0.08 1.02 ± 0.09 0.73 ± 0.13 1.49 ± 0.32^b $P < 0.005$ NS NS Cortisol (ng/mL) 11.6 ± 1.8 12.2 ± 2.1 76.3 ± 17.2^a 36.2 ± 7.1^a NS $P < 0.001$ NS T4 (ng/mL) 87.7 ± 10.9 74.3 ± 8.8 65.5 ± 8.7 43.4 ± 4.6^a NS $P < 0.05$ NS T3 (ng/mL) 0.18 ± 0.02 0.16 ± 0.02 0.55 ± 0.16^a 0.30 ± 0.03^a NS $P < 0.001$ NS Leptin (ng/mL) 0.90 ± 0.08 0.76 ± 0.04 1.06 ± 0.07 0.71 ± 0.04^b $P < 0.005$ NS NS CTX (ng/mL) 0.76 ± 0.04 0.68 ± 0.07 0.99 ± 0.24 0.43 ± 0.06^b $P < 0.05$ NS NS NS | Metacarpus/phalanges (cm) | 13.2 ± 0.3 | 12.2 ± 0.3 ^b | 14.4 ± 0.2^{a} | 13.2 ± 0.6 ^b | <i>P</i> < 0.01 | <i>P</i> < 0.005 | NS |
| Insulin (ng/mL) 0.30 ± 0.06 0.05 ± 0.01^b 0.34 ± 0.17 0.04 ± 0.01^b $P < 0.005$ NS NS Glucose (mmol/L) 0.71 ± 0.08 1.02 ± 0.09 0.73 ± 0.13 1.49 ± 0.32^b $P < 0.005$ NS NS Cortisol (ng/mL) 11.6 ± 1.8 12.2 ± 2.1 76.3 ± 17.2^a 36.2 ± 7.1^a NS $P < 0.001$ NS T4 (ng/mL) 87.7 ± 10.9 74.3 ± 8.8 65.5 ± 8.7 43.4 ± 4.6^a NS $P < 0.05$ NS T3 (ng/mL) 0.18 ± 0.02 0.16 ± 0.02 0.55 ± 0.16^a 0.30 ± 0.03^a NS $P < 0.001$ NS Leptin (ng/mL) 0.90 ± 0.08 0.76 ± 0.04 1.06 ± 0.07 0.71 ± 0.04^b $P < 0.005$ NS NS CTX (ng/mL) 0.76 ± 0.04 0.68 ± 0.07 0.99 ± 0.24 0.43 ± 0.06^b $P < 0.05$ NS NS NS | Radius (cm) | 10.8 ± 0.3 | 10.3 ± 0.4 | 12.0 ± 0.3^{a} | 11.2 ± 0.5 | NS | <i>P</i> < 0.05 | NS |
| Glucose (mmol/L) 0.71 ± 0.08 1.02 ± 0.09 0.73 ± 0.13 1.49 ± 0.32^b $P < 0.005$ NS NS Cortisol (ng/mL) 11.6 ± 1.8 12.2 ± 2.1 76.3 ± 17.2^a 36.2 ± 7.1^a NS $P < 0.001$ NS T4 (ng/mL) 87.7 ± 10.9 74.3 ± 8.8 65.5 ± 8.7 43.4 ± 4.6^a NS $P < 0.05$ NS T3 (ng/mL) 0.18 ± 0.02 0.16 ± 0.02 0.55 ± 0.16^a 0.30 ± 0.03^a NS $P < 0.001$ NS Leptin (ng/mL) 0.90 ± 0.08 0.76 ± 0.04 1.06 ± 0.07 0.71 ± 0.04^b $P < 0.005$ NS NS CTX (ng/mL) 0.76 ± 0.04 0.68 ± 0.07 0.99 ± 0.24 0.43 ± 0.06^b $P < 0.05$ NS NS NS Osteocalcin (ng/mL) 12.2 ± 1.2 12.9 ± 0.3 11.9 ± 1.5 13.1 ± 0.8 NS NS | Humerus (cm) | 9.1 ± 0.3 | 8.8 ± 0.4 | 10.0 ± 0.5 | 10.0 ± 0.5 | NS | <i>P</i> < 0.05 | NS |
| $ \begin{array}{llllllllllllllllllllllllllllllllllll$ | Insulin (ng/mL) | 0.30 ± 0.06 | 0.05 ± 0.01b | 0.34 ± 0.17 | 0.04 ± 0.01b | <i>P</i> < 0.005 | NS | NS |
| $ \begin{array}{llllllllllllllllllllllllllllllllllll$ | Glucose (mmol/L) | 0.71 ± 0.08 | 1.02 ± 0.09 | 0.73 ± 0.13 | 1.49 ± 0.32^{b} | P < 0.005 | NS | NS |
| T3 (ng/mL) 0.18 ± 0.02 0.16 ± 0.02 0.55 ± 0.16^a 0.30 ± 0.03^a NS $P < 0.001$ NS Leptin (ng/mL) 0.90 ± 0.08 0.76 ± 0.04 1.06 ± 0.07 0.71 ± 0.04^b $P < 0.005$ NS NS CTX (ng/mL) 0.76 ± 0.04 0.68 ± 0.07 0.99 ± 0.24 0.43 ± 0.06^b $P < 0.05$ NS $P < 0.0$ Osteocalcin (ng/mL) 12.2 ± 1.2 12.9 ± 0.3 11.9 ± 1.5 13.1 ± 0.8 NS NS | Cortisol (ng/mL) | 11.6 ± 1.8 | 12.2 ± 2.1 | 76.3 ± 17.2a | 36.2 ± 7.1^{a} | NS | <i>P</i> < 0.001 | NS |
| Leptin (ng/mL) 0.90 ± 0.08 0.76 ± 0.04 1.06 ± 0.07 0.71 ± 0.04^b $P < 0.005$ NS NS CTX (ng/mL) 0.76 ± 0.04 0.68 ± 0.07 0.99 ± 0.24 0.43 ± 0.06^b $P < 0.05$ NS $P < 0.0$ Osteocalcin (ng/mL) 12.2 ± 1.2 12.9 ± 0.3 11.9 ± 1.5 13.1 ± 0.8 NS NS | T4 (ng/mL) | 87.7 ± 10.9 | 74.3 ± 8.8 | 65.5 ± 8.7 | 43.4 ± 4.6^{a} | NS | <i>P</i> < 0.05 | NS |
| CTX (ng/mL) 0.76 ± 0.04 0.68 ± 0.07 0.99 ± 0.24 0.43 ± 0.06^b $P < 0.05$ NS $P < 0.0$ Osteocalcin (ng/mL) 12.2 ± 1.2 12.9 ± 0.3 11.9 ± 1.5 13.1 ± 0.8 NS NS | T3 (ng/mL) | 0.18 ± 0.02 | 0.16 ± 0.02 | 0.55 ± 0.16^{a} | 0.30 ± 0.03^{a} | NS | <i>P</i> < 0.001 | NS |
| Osteocalcin (ng/mL) 12.2 ± 1.2 12.9 ± 0.3 11.9 ± 1.5 13.1 ± 0.8 NS NS NS | Leptin (ng/mL) | 0.90 ± 0.08 | 0.76 ± 0.04 | 1.06 ± 0.07 | 0.71 ± 0.04^{b} | <i>P</i> < 0.005 | NS | NS |
| | CTX (ng/mL) | 0.76 ± 0.04 | 0.68 ± 0.07 | 0.99 ± 0.24 | 0.43 ± 0.06 ^b | <i>P</i> < 0.05 | NS | <i>P</i> < 0.05 |
| Calcium (mmol/L) $2.34 \pm 0.28 2.97 \pm 0.15 2.73 \pm 0.32 3.38 \pm 0.28 P = 0.053 NS NS$ | Osteocalcin (ng/mL) | 12.2 ± 1.2 | 12.9 ± 0.3 | 11.9 ± 1.5 | 13.1 ± 0.8 | NS | NS | NS |
| | Calcium (mmol/L) | 2.34 ± 0.28 | 2.97 ± 0.15 | 2.73 ± 0.32 | 3.38 ± 0.28 | P = 0.053 | NS | NS |

a Significant difference from fetuses of the same treatment at 129 days of gestation, two-way ANOVA (P < 0.05); b Significant difference from sham fetuses at the same gestational age (P < 0.05). F, female; M, male; NS, not significant; S, singleton; T, twin.

Tissue collection

The PX and sham fetuses were delivered by Caesarean section under general anaesthesia (20 mg/kg sodium pentobarbitone i.v. to the ewe) at either 127–131 days (129 days; PX n = 6, sham n = 8) or 142–145 days of gestation (144 days; PX n = 5, sham n = 5). At delivery, 5 mL of blood samples were taken by venepuncture of the umbilical artery and placed into EDTA-containing tubes. The samples were centrifuged for 5 min at 1000 g at 4°C, and the plasma aliquots were stored at -20°C until analysis.

The fetuses were administered with a lethal dose of barbiturate (200 mg/kg sodium pentobarbitone), and morphometric measurements were made at dissection during post-mortem. Crown-rump length (CRL) and lengths of the hind-limb (femur, tibia and metatarsus/phalanges) and fore-limb (humerus, radius and metacarpus/phalanges) were measured. The metatarsal bone from one hind-limb of each fetus was immediately frozen in liquid nitrogen and stored at -80° C until analysis. In the sheep, each hind-limb has one elongated metatarsal bone formed from the fusion of metatarsi III and IV. Metatarsi I and V are absent, and metatarsus II is a small vestigial bone. At delivery, there was no evidence of pancreatic remnants in any of the PX fetuses.

Biochemical analyses

Umbilical plasma insulin concentration was determined using an ELISA kit (Mercodia, Uppsala, Sweden); the intraassay coefficient of variation was 9%, and the minimum level of detection was 0.025 ng/mL. Plasma cortisol and leptin concentrations were measured by RIA as previously described (Robinson et al. 1983, Blache et al. 2000). The intra-assay coefficients of variation were 11 and 5%, and the minimum levels of detection were 1.5 and 0.09 ng/mL, respectively. Plasma triiodothyronine (T3) and thyroxine (T4) concentrations were determined by RIA kits (MP Biomedicals, Loughborough, UK); the intra-assay coefficients of variation were 3 and 5%, and the minimum levels of detection were 0.14 and 7.0 ng/mL, respectively. Plasma glucose concentration was measured using a Yellow Springs glucose analyser (2300 Statplus, YSI Incorporated, Yellow Springs, Ohio, USA).

Plasma levels of total osteocalcin and the degradation products of C-terminal telopeptides of type I collagen (CTX) were determined by ELISA (Immunodiagnostics Systems Ltd, Boldon, UK). The lower limits of detection of osteocalcin and CTX were 0.5 and 0.02 ng/mL, respectively, and all measurements were made in a single assay.



Total plasma calcium was measured by a Siemens Dimension RXL auto-analyser using Siemens reagents and calibrators (Siemens Healthcare, Camberley, UK).

Micro-computed tomography

The fetal metatarsi were scanned using an Xtek Benchtop 160Xi scanner (Xtek Systems Ltd, Tring, UK) equipped with a Hamamatsu C7943 X-ray flat panel sensor (Hamamatsu Photonics, Welwyn Garden City, UK) as described previously (Lanham et al. 2011b). Reconstructed images were analysed using VGStudio Max 1.2.1 software (Volume Graphics GmbH, Heidelberg, Germany) to calculate the bone volume to total volume ratio (BV/TV), bone surface area to bone volume ratio (BS/BV), trabecular (Tb) thickness, spacing and number per unit length. Using a custom written package and the Visilog Quantification + package (both Noesis, Crolles, France) within the Amira 4.1.2 package (Mercury Computer System Inc., Chelmsford, USA), measurements were also made of porosity, Euler number (a measure of connectivity), structural model index (a measure of surface convexity where an ideal plate, cylinder and sphere have SMI values of 0, 3 and 4, respectively), Tb pattern factor (the relative concave or convex nature of the total bone surface, where concavity indicates connectivity and convexity indicates isolated, disconnected structures), average object (Av Obj) number and area (indicators of structural connectivity, where high connectivity results in few and large objects, while fragmentation results in large numbers of smaller), degree of anisotropy (DOA, orientation of trabeculae) and fractal dimension.

Bone strength testing

Mechanical bone strength was assessed in a subset of fetuses at 144 days of gestation (n=4 from each treatment group). The midshaft strength of metatarsal cortical bone was tested using an electromagnetic bend test instrument (Bose Electroforce 3200, Bose Corporation, Minnesota, USA). The bones were placed with anterior surface down on two supports, 40 mm apart and equidistant from the bone ends. Each bone was loaded centrally at a constant rate (6 mm/min) until fracture. In order to test the strength of Tb bone, a small block of Tb bone ($3 \times 3m \times 6 \text{ mm}^3$) was cut from the distal end of the metatarsal. The sample was placed between two supports and loaded at a constant rate (1 mm/min) until failure. Load–displacement curves were used to calculate maximum load at fracture, maximum displacement at fracture, stiffness and stress.

Stiffness was determined as the slope of the linear portion of the load–displacement curve, while stress was calculated as the maximum load divided by the cross-sectional area as measured by micro-CT.

Statistical analysis

Data are presented as mean \pm s.E.M. and were assessed for normality using the D'Agostino–Pearson's test. Log₁₀-transformed data were analysed where necessary. The effect of PX at 129 and 144 days of gestation was assessed by two-way ANOVA with treatment and gestational age as factors, followed by the Tukey's test. Bone strength properties were compared between treatment groups at 144 days of gestation by Student's *t*-test. Relationships between variables were determined by Spearman correlation. Plasma hormone concentrations below the minimum level of detection were assigned the minimum value for the presentation and statistical analysis of the data. Statistical significance was accepted at P < 0.05.

Results

Plasma hormone and metabolite concentrations

Umbilical plasma insulin concentration in the PX fetuses was near to the minimum limit of assay detection and was lower than that observed in the sham control fetuses at both gestational ages (log_{10} insulin, Table 1, P < 0.05). Plasma concentrations of leptin and CTX were lower, and glucose was higher, in the PX compared to sham fetuses at 144 days of gestation (Table 1, P < 0.05). Towards term, a decrease in plasma T4 in the PX fetuses (P < 0.05) and increments in plasma concentrations of cortisol and T3 in both sham and PX fetuses (log_{10} cortisol and T3, P < 0.05) were observed with no differences in these concentrations between the treatment groups at either gestational age (Table 1). There were no significant effects of gestational age or treatment on plasma calcium or osteocalcin concentrations, although there was a tendency for higher plasma calcium concentration in the PX compared to sham fetuses which did not reach significance (log₁₀ calcium, *P*= 0.053).

When all data were combined, regardless of treatment or gestational age (n=24 fetuses), significant relationships were observed between plasma insulin and plasma concentrations of glucose (R=-0.59, P < 0.005), leptin (R=+0.57, P < 0.005) and CTX (R=+0.42, P < 0.005). Plasma leptin was negatively correlated with osteocalcin



© 2021 The authors

Printed in Great Britain

Published by Bioscientifica Ltd.

(R=-0.45, P<0.05). Overall, plasma cortisol concentration correlated positively with plasma T3 (R=+0.62, P<0.005) and negatively with plasma T4 (R=-0.52, P<0.01). Positive correlations were observed between plasma T3 and calcium concentrations (R=+0.44, P<0.05) and between plasma T4 and CTX concentrations (R=+0.44, P<0.05).

Fetal morphology

Fetal body weight and CRL increased towards term in both treatment groups. Overall, body weight was reduced in the PX compared to sham fetuses, although the *post hoc* analysis failed to identify significant differences with treatment at either gestational age (Table 1, P = 0.067 at 144 days). Total and individual bone lengths of the fore- and hind-limbs increased with gestational age in the sham, but not PX fetuses (Table 1, P < 0.05). At 144 days of gestation, measurements of the total hind-limb, metatarsus-phalanges, tibia and metacarpus-phalanges were lower in the PX compared to sham fetuses (Table 1, P < 0.05); the length of the metacarpus-phalanges was also reduced in the PX fetuses studied at 129 days of gestation (Table 1, P < 0.05).

Metatarsal bone structure

Fetal pancreatectomy had significant effects on the aspects of bone structure, including BV/TV and BS/BV ratios, Tb spacing and thickness, Av Obj number and area, DOA and porosity (Fig. 1, P < 0.05). In the PX fetuses, BV/TV ratio, Tb thickness, Av Obj area, DOA and porosity were higher, and BS/BV ratio, Tb spacing and Av Obj number were lower, compared to the sham fetuses at 144 days of gestation (Fig. 1, P < 0.05). Between 129 and 144 days of gestation, Tb spacing increased in the sham fetuses, and porosity increased in the PX fetuses (Table 2, P < 0.05). There were no effects of treatment or gestational age on the measurements of Euler, SMI, Tb number, Tb pattern factor or fractal dimension (Table 2). Representative images of longitudinal sections of metatarsal bones in PX and sham fetuses at 129 and 144 days of gestation are presented in Fig. 2.

Overall, relationships were observed between plasma insulin and BS/BV ratio (R=+0.50, P < 0.05), Av Obj number (R=+0.47, P < 0.05), porosity (R=-0.44, P < 0.05) and Euler (R=-0.51, P < 0.05) and between plasma leptin and BV/TV ratio (R=-0.55, P < 0.01), BS/BV ratio (R=+0.61, P < 0.005), Av Obj number (R=+0.51, P < 0.05) and area (R=-0.54, P < 0.01), Tb spacing (R=+0.47, P < 0.05) and thickness (R=-0.67, P < 0.0005), porosity (R=-0.52, P < 0.01), DOA (R=-0.50, P < 0.05) and fractal dimension (R=-0.49, P < 0.05).




Figure 1 Mean (\pm s.e.m.) BV/TV (A), ratio of BS/BV (B), Tb spacing (C), Tb thickness (D), Av Obj number (E), average object area (F), porosity (G) and DOA (H) in the metatarsal bone of sham and PX fetuses at 129 and 144 days of gestation. *Significant difference from sham fetuses at the same gestational age (P < 0.05). †Significant difference from fetuses of the same treatment at 129 days of gestation (P < 0.05). BV/TV, bone volume–total volume ratio; BS/BV, bone surface area–bone volume ratio; Tb, trabecular; Av Obj, average object; DOA, degree of anisotropy.

Metatarsal bone strength

Table 3 shows that, compared to the sham fetuses, there were no significant differences in the maximum load, maximum displacement, stiffness or stress in the midshaft cortical bone between the sham and PX fetuses at 144 days



Table 2 Mean (\pm s.E.M.) measurements of metatarsal trabecular bone structure in sham and PX sheep fetuses at 129 and 144 days of gestation. No significant differences identified by two-way ANOVA (P > 0.05).

| Gestational age (days) | | 129 | 144 | | |
|---------------------------|------------------|------------------|------------------|------------------|--|
| Treatment | Sham | PX | Sham | PX | |
| Number of fetuses | 8 | 6 | 5 | 5 | |
| Trabecular number (mm) | 3.23 ± 0.18 | 3.46 ± 0.12 | 3.24 ± 0.17 | 3.19 ± 0.18 | |
| Trabecular pattern factor | -4.14 ± 0.51 | -4.33 ± 0.75 | -2.37 ± 0.79 | -4.79 ± 1.76 | |
| Structural model index | 0.15 ± 0.02 | 0.14 ± 0.02 | 0.09 ± 0.02 | 0.16 ± 0.04 | |
| Euler | -1897 ± 432 | -1113 ± 268 | -1360 ± 301 | -985 ± 159 | |
| Fractal dimension | 2.51 ± 0.04 | 2.51 ± 0.03 | 2.37 ± 0.04 | 2.50 ± 0.05 | |

of gestation. The distal Tb bone in the PX fetuses fractured at a greater maximum load, per unit area, compared to that in the sham fetuses (P < 0.05; Table 3). Furthermore, Tb bone in the PX fetuses showed higher stiffness than in the sham fetuses (P < 0.05; Table 3). Maximum displacement and stress in Tb bone did not differ between sham and PX fetuses (Table 3).

When all the data were combined (n=8 fetuses), significant correlations were observed between plasma T4 and both maximum displacement (R=-0.76, P<0.05) and stiffness (R=+0.74, P<0.05) in midshaft cortical bone. Stress in cortical bone was correlated with plasma concentrations of calcium (R=+0.96, P<0.01), CTX (R=-0.83, P<0.05) and osteocalcin (R=+0.81, P<0.05). In distal Tb bone, significant relationships were observed between plasma T3 and both maximal load (R=-0.86, P<0.05) and stress (R=-0.93, P<0.01).

Discussion

Pancreas deficiency in the sheep fetus over the last 20–35 days of gestation reduced body weight and growth of the appendicular skeleton. In the hind-limb, the shorter metatarsal bone length was associated with changes to

the microarchitecture of the Tb bone. The increase in Tb BV/TV ratio indicated a more compact bone structure with a relatively low internal bone surface area (BS/BV ratio), likely due to an increase in Tb thickness. Although the trabeculae were larger, they were more closely spaced together within the bone of the pancreas-deficient fetus, with enhanced porosity evident near term. The increase in DOA also indicated that the spatial organization of the trabeculae was predominantly uni-directional, rather than multi-directional, in orientation. Many of the effects of PX were significant at 144 days, and not 129 days, of gestation which may reflect the duration of pancreas deficiency. In a subset of fetuses studied near term, mechanical testing showed that distal Tb bone samples were more stiff and fractured at a greater maximal load in the PX compared with sham fetuses. Overall, these indices demonstrated that, while the bone size was reduced in response to pancreas deficiency in utero, metatarsal Tb bone structure was more condensed with greater structural connectivity which may be a key adaptation to maintain bone strength in precocial offspring. Use of a large animal model and measurement of a number of structural, biochemical and mechanical end-points are key strengths of this study which enabled the assessment of the consequences of hypoinsulinaemia, secondary to pancreas deficiency, in a precocial species




Figure 2Representative images of longitudinal sections of the distal metatarsal bone showing trabecular structure and secondary ossification sites in sham and PX fetuses at (A) 129 and (B) 144 days of gestation. Bars represent 5 mm.



Table 3 Mean (\pm s.E.M.) measurements of bone strength in metatarsal midshaft cortical and distal trabecular bone from sham and PX fetuses at 144 days of gestation.

| Treatment | Sham | PX |
|---------------------------|-----------------|--------------------------|
| Number of fetuses | 4 | 4 |
| Midshaft cortical bone | | |
| Maximum load (N) | 135.8 ± 11.7 | 132.3 ± 8.2 |
| Maximum displacement (mm) | 2.99 ± 0.37 | 3.46 ± 0.21 |
| Stiffness (N/mm) | 81.0 ± 17.3 | 55.2 ± 13.0 |
| Stress (N/mm²) | 2.04 ± 0.10 | 2.15 ± 0.24 |
| Distal trabecular bone | | |
| Maximum load (N) | 21.0 ± 6.2 | 56.2 ± 11.7 ^a |
| Maximum displacement (mm) | 0.69 ± 0.11 | 0.84 ± 0.03 |
| Stiffness (N/mm) | 41.4 ± 3.1 | 90.1 ± 1.2^{a} |
| Stress (N/mm²) | 282.8 ± 54.2 | 489.0 ± 132.9 |

^aSignificant difference, Student's t-test (P < 0.05).

over a period of late gestation. As a limitation, the relatively low number of fetuses in each treatment group may have weakened the statistical analysis and accounted for tendencies in plasma calcium and glucose concentrations.

In this study, the role of insulin in the control of bone growth and development in the fetus near term was examined by removal of the fetal pancreas which caused hypoinsulinaemia. Previous studies in fetal sheep have shown that pancreas deficiency reduces fore- and hindlimb lengths, and the daily increment in CRL measured using indwelling growth catheters, and that axial and appendicular growth can be restored to normal rates by insulin replacement (Fowden et al. 1989). In the present study, however, there were no effects of pancreatectomy on CRL, although this was a single measurement taken in a relatively small number of fetuses at delivery and the microstructure of the vertebrae was not investigated. Normalization of growth by insulin replacement in the PX sheep fetus suggests that the primary deficiency of PX in relation to bone growth appears to be hypoinsulinaemia. However, specific skeletal effects may be mediated via other insulin-dependent factors. Indeed, insulin replacement is also likely to normalize other endocrine and metabolite changes in the PX fetus that may contribute to the effects of pancreas deficiency on bone growth and development.

In adult life, insulin influences skeletal remodelling via actions on the proliferation, differentiation and activity of both bone and cartilage cell types (Pramojanee *et al.* 2014). Much less is known, however, about the targets for insulin action before birth, especially in precocial, large animals. In the present study, the plasma concentration of osteocalcin, a marker of osteoblast activity and bone formation, was unchanged by pancreas deficiency while CTX, a marker of osteoclast activity and bone resorption, was lower in the

PX fetuses. Plasma CTX increases in intact sheep fetuses over the last month of gestation (Lanham *et al.* 2011*b*) and this developmental rise appeared to be prevented in the PX fetus. Circulating concentrations of both CTX and osteocalcin are reduced in mice with targeted deletion of the insulin receptor in osteoblasts (Ferron *et al.* 2010, Fulzele *et al.* 2010). At 3–12 weeks of postnatal age, BV/TV ratio was reduced in the femur of these mutant mice with fewer, thinner trabeculae and reductions in osteoblast number and resorption sites (Ferron *et al.* 2010, Fulzele *et al.* 2010). Further research is required to elucidate the cellular and molecular mechanisms responsible for changes in bone development associated with pancreas, and specifically insulin, deficiency *in utero* in both precocial and altricial species.

In addition to the direct effects of hypoinsulinaemia, there are a number of metabolic and other endocrine factors that may be responsible for the changes in bone growth and development due to intrauterine pancreas deficiency. In fetal sheep, hypoinsulinaemia induced either by pancreas removal or streptozocin treatment is associated with hyperglycaemia and decreases in umbilical glucose uptake (both absolute and relative to fetal body weight), fetal glucose utilization and the fraction of umbilical oxygen uptake used to oxidize glucose carbon, all of which can be restored to normal levels by insulin replacement (Fowden & Hay 1988, Hay et al. 1989, Fowden & Forhead 2012). In these models of insulin deficiency, the reduction in glucose utilization leads to greater use of other substrates for metabolism, including amino acids. This means that there are less amino acids available for protein synthesis in bone and other tissues. Furthermore, the increase in circulating glucose concentration that accompanies insulin deficiency may contribute to the changes in bone structure observed in the PX fetuses as more severe hyperglycaemia in diabetic models and studies in vitro is associated with abnormalities in bone development (Dienelt & zur Nieden 2011, Seref-Ferlengez et al. 2016). It is difficult, however, to establish the relative roles of hypoinsulinaemia and hyperglycaemia in diabetic models in vivo, and variable results have been reported from a range of experimental approaches in vitro (reviewed by Seref-Ferlengez et al. 2016). In a mouse model where the insulin receptor was deleted but blood glucose concentration was normalized by the expression of human insulin receptor transgene in the pancreas, liver and brain, bone development was relatively normal at 4-5 months of postnatal age (Irwin et al. 2006). Although the insulin receptor was not present in bone, there were no differences in cortical or Tb structure as assessed by micro-CT. Overall, the findings suggest that hyperglycaemia may



be responsible, at least in part, for the abnormal skeletal growth associated with impaired insulin signalling in adulthood. It was also noted, however, that expression of the insulin-like growth factor type I (IGFI) receptor was upregulated in the bone of mutant mice which may have driven skeletal development in response to IGFs and/or the high circulating concentrations of insulin seen in this model (Irwin *et al.* 2006). There are, therefore, a variety of other factors that affect bone structure which need to be considered in models of hypoinsulinaemia, including targeted gene mutations.

The IGFs may contribute to the changes in bone structure observed in the PX fetus (Agrogiannis et al. 2014, Pramojanee et al. 2014, Yakar et al. 2018). Although not measured in the present study, it has been shown previously that plasma concentrations of IGFI are decreased and insulin-like growth factor II (IGFII) are increased in the PX sheep fetus, with positive and negative correlations observed between plasma insulin and concentrations of IGFI and IGFII, respectively (Gluckman et al. 1987). Similarly, in a clinical case of transient neonatal diabetes $mellitus\,where\,the\,infant\,was\,born\,with\,IUGR\,and\,umbilical$ plasma concentrations of insulin were undetectable, IGFI was lower than normal and IGFII was within the normal range (Blethen et al. 1981). In fetal sheep, IGFs and their binding proteins are co-localized in the epiphyseal growth plates, and IGFI and IGFII have been shown in vitro to stimulate the proliferation of chondrocytes isolated from the growth plates (Hill & de Sousa 1990, de los Rios & Hill 1999). In this model system, insulin also increases the expression of IGF-binding protein-3 which may modify the bioavailability and paracrine actions of IGFs within the developing bone (Rios & Hill 2000). IGFI has been shown to increase collagen and DNA synthesis and bone matrix formation in vitro in skull calvariae taken from rat fetuses close to term (Hock et al. 1988). In vivo infusion of IGFI in sheep fetuses promotes epiphyseal development, although there were no overall effects on limb length or weight, and plasma insulin and IGFII concentrations were reduced (Lok et al. 1996). In fetal mice with deletions in IGFI or the type 1 receptor, IGF-1R, growth retardation was associated with a delay in skeletal ossification, both of which were more marked in the IGF-1R mutants (Liu et al. 1993). Analysis of Tb bone structure using micro-CT showed reductions in BV/TV ratio, Tb spacing and DOA in the tibia of IGFIdeficient mouse fetuses (Burghardt et al. 2007).

In the present study, plasma leptin concentration was reduced in the PX fetus and correlated with several of the Tb bone indices. Like insulin, leptin has been proposed as a mechanism linking bone remodelling with nutrient availability before and after birth (Forhead & Fowden 2009, Devlin & Bouxsein 2012), and a relationship between circulating insulin and adipose leptin mRNA has been shown previously in fetal sheep (Devaskar *et al.* 2002). Infusion of supraphysiological concentrations of leptin influences metatarsal Tb structure in fetal sheep, although leptin receptor antagonism only affected the development of the vertebra, and not the metatarsal or femur (De Blasio *et al.* 2018). Further studies are required to determine the effects of intrauterine pancreas deficiency on leptin signalling within the developing skeleton and to assess the relative contribution of low circulating leptin on bone structure and function in this model.

The changes in Tb bone structure and mechanical strength observed in the pancreas-deficient ovine fetus resemble those seen in skeletal growth retardation associated with hypothyroidism *in utero* (Lanham *et al.* 2011*b*) and indicate that there may be a common mechanism that leads to modified skeletal growth and development in both models of fetal endocrine deficiency. Similarities in bone development occurred even though the hypothyroid sheep fetus has high circulating concentrations of insulin (Harris *et al.* 2017), and plasma thyroid hormones appear to be unaffected by pancreas deficiency. Local hormone concentrations and the activity of signalling pathways, however, including those of IGF and other growth factors, remain to be determined in the developing Tb bone of both pancreas- and thyroid-deficient sheep fetuses.

Insulin and thyroid hormones are important anabolic signals in the fetus that respond to changes in nutrient levels and promote tissue growth when substrates are available (Sferruzzi-Perri et al. 2013). In conditions of undernutrition in utero, circulating concentrations of these hormones are reduced (Sferruzzi-Perri et al. 2013), and the resultant change in skeletal development, by common or different mechanisms, may favour a more compact bone structure that maintains mechanical integrity in a smaller bone. Indeed, in both sheep models of pancreas and thyroid deficiency in utero, mechanical stress tests showed that metatarsal Tb bone was stronger per unit area, albeit more stiff and brittle, than in control fetuses (Lanham et al. 2011b). During these endocrine conditions, changes in Tb bone microstructure may be an important adaptation that preserves bone strength in the face of limited availability of substrates for bone growth. This is likely to be of particular importance in a precocial species like the sheep where the neonatal skeleton is required for locomotion from immediately after birth. In contrast, bone development and strength may be relatively more compromised by pancreas deficiency in



altricial rodents and human offspring that do not require weight-bearing bones at birth. Importantly, the need for skeletal maturity and function at birth may account for some of the differences in fetal bone development identified between mammalian species (Lanham *et al.* 2011*a*).

To conclude, fetal hypoinsulinaemia associated with pancreas deficiency retarded growth of the limbs and adapted the developing bone to a more compact and connected structure that maintained mechanical strength. Further studies are required to establish the molecular mechanisms responsible and whether the bone phenotype established in response to pancreas deficiency *in utero* has longer-term consequences for postnatal bone development, at a time when there are changes to nutrient supply and growth rate, endocrine environment and locomotive activity.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work was supported by the BBSRC (grant number S18103) and Research into Ageing (grant number 253).

Acknowledgements

The authors are grateful to the members of the Universities of Cambridge, Southampton and Western Australia who provided technical assistance in this study. Plasma calcium concentration was measured by Dr Keith Burling, Department of Clinical Biochemistry, Addenbrooke's Hospital, Cambridge.

References

- Agrogiannis GD, Sifakis S, Patsouris ES & Konstantinidou AE 2014
 Insulin-like growth factors in embryonic and fetal growth and skeletal development (Review). *Molecular Medicine Reports* 10 579–584. (https://doi.org/10.3892/mmr.2014.2258)
- Blache D, Tellam RL, Chagas LM, Blackberry MA, Vercoe PE & Martin GB 2000 Level of nutrition affects leptin concentrations in plasma and cerebrospinal fluid in sheep. *Journal of Endocrinology* **165** 625–637. (https://doi.org/10.1677/joe.0.1650625)
- Blethen SL, White NH, Santiago JV & Daughaday WH 1981 Plasma somatomedins, endogenous insulin secretion, and growth in transient neonatal diabetes mellitus. *Journal of Clinical Endocrinology and Metabolism* **52** 144–147. (https://doi.org/10.1210/jcem-52-1-144)
- Boehmer BH, Limesand SW & Rozance PJ 2017 The impact of IUGR on pancreatic islet development and β-cell function. *Journal of Endocrinology* **235** R63–R76. (https://doi.org/10.1530/JOE-17-0076)

- Brinsmead MW & Thorburn GD 1982 Effect of streptozotocin on foetal lambs in mid-pregnancy. *Australian Journal of Biological Sciences* **35** 517–525. (https://doi.org/10.1071/bi9820517)
- Burghardt AJ, Wang Y, Elalieh H, Thibault X, Bikle D, Peyrin F & Majumdar S 2007 Evaluation of fetal bone structure and mineralization in IGF-I deficient mice using synchrotron radiation microtomography and Fourier transform infrared spectroscopy. *Bone* **40** 160–168. (https://doi.org/10.1016/j.bone.2006.06.017)
- Comline RS & Silver M 1972 The composition of foetal and maternal blood during parturition in the ewe. *Journal of Physiology* **222** 233–256. (https://doi.org/10.1113/jphysiol.1972.sp009795)
- De Blasio MJ, Lanham SA, Blache D, Oreffo ROC, Fowden AL & Forhead AJ 2018 Sex- and bone-specific responses in bone structure to exogenous leptin and leptin receptor antagonism in the ovine fetus. *American Journal of Physiology: Regulatory, Integrative and Comparative Physiology* 314 R781–R790. (https://doi.org/10.1152/ajpregu.00351.2017)
- de los Rios P & Hill DJ 1999 Cellular localization and expression of insulin-like growth factors (IGFs) and IGF binding proteins within the epiphyseal growth plate of the ovine fetus: possible functional implications. *Canadian Journal of Physiology and Pharmacology* **77** 235–249. (https://doi.org/10.1139/y99-015)
- Devaskar SU, Anthony R & Hay W 2002 Ontogeny and insulin regulation of fetal ovine white adipose tissue leptin expression. *American Journal of Physiology: Regulatory, Integrative and Comparative Physiology* **282** R431–R438. (https://doi.org/10.1152/ajpregu.2002.282.2.R431)
- Devlin MJ & Bouxsein ML 2012 Influence of pre- and peri-natal nutrition on skeletal acquisition and maintenance. *Bone* **50** 444–451. (https://doi.org/10.1016/j.bone.2011.06.019)
- Dienelt A & zur Nieden NI 2011 Hyperglycemia impairs skeletogenesis from embryonic stem cells by affecting osteoblast and osteoclast differentiation. *Stem Cells and Development* **20** 465–474. (https://doi.org/10.1089/scd.2010.0205)
- Ferron M, Wei J, Yoshizawa T, Fattore AD, DePinho RA, Teti A, Ducy P & Karsenty G 2010 Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. *Cell* **142** 296–308. (https://doi.org/10.1016/j.cell.2010.06.003)
- Forhead AJ & Fowden AL 2009 The hungry fetus? Role of leptin as a nutritional signal before birth. *Journal of Physiology* **587** 1145–1152. (https://doi.org/10.1113/jphysiol.2008.167072)
- Fowden AL 1992 The role of insulin in fetal growth. *Early Human Development* **29** 177–181. (https://doi.org/10.1016/0378-3782(92)90135-4)
- Fowden AL 1993 Insulin deficiency: effects on fetal growth and development. *Journal of Paediatrics and Child Health* **29** 6–11. (https://doi.org/10.1111/j.1440-1754.1993.tb00428.x)
- Fowden AL & Comline RS 1984 The effects of pancreatectomy on the sheep fetus in utero. *Quarterly Journal of Experimental Physiology* **69** 319–330. (https://doi.org/10.1113/expphysiol.1984.sp002808)
- Fowden AL & Forhead AJ 2012 Insulin deficiency alters the metabolic and endocrine responses to undernutrition in fetal sheep near term. Endocrinology **153** 4008–4018. (https://doi.org/10.1210/en.2012-1063)
- Fowden AL & Hay WW 1988 The effects of pancreatectomy on the rates of glucose utilization, oxidation and production in the sheep fetus. *Quarterly Journal of Experimental Physiology* **73** 973–984. (https://doi.org/10.1113/expphysiol.1988.sp003231)
- Fowden AL, Hughes P & Comline RS 1989 The effects of insulin on the growth rate of the sheep fetus during late gestation. *Quarterly Journal of Experimental Physiology* **74** 703–714. (https://doi.org/10.1113/expphysiol.1989.sp003322)
- Fowden AL, Szemere J, Hughes P, Gilmour RS & Forhead AJ 1996 The effects of cortisol on the growth rate of the sheep fetus during late gestation. *Journal of Endocrinology* **151** 97–105. (https://doi.org/10.1677/joe.0.1510097)
- Fulzele K, Riddle RC, DiGirolamo DJ, Cao X, Wan C, Chen D, Faugere MC, Aja S, Hussain MA, Brüning JC, *et al.* 2010 Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. *Cell* **142** 309–319. (https://doi.org/10.1016/j.cell.2010.06.002)



© 2021 The authors

Printed in Great Britain

Published by Bioscientifica Ltd

- Gluckman PD, Butler JH, Comline R & Fowden A 1987 The effects of pancreatectomy on the plasma concentrations of insulin-like growth factors 1 and 2 in the sheep fetus. *Journal of Developmental Physiology* **9** 79–88.(https://pubmed.ncbi.nlm.nih.gov/3549860/)
- Harris SE, De Blasio MJ, Davis MA, Kelly AC, Davenport HM, Wooding FBP,
 Blache D, Meredith D, Anderson M, Fowden AL, et al. 2017
 Hypothyroidism in utero stimulates pancreatic beta cell proliferation
 and hyperinsulinaemia in the ovine fetus during late gestation. *Journal of Physiology* 595 3331–3343. (https://doi.org/10.1113/JP273555)
- Hay WW, Meznarich HK & Fowden AL 1989 The effects of streptozotocin on rates of glucose utilization, oxidation, and production in the sheep fetus. *Metabolism: Clinical and Experimental* **38** 30–37. (https://doi.org/10.1016/0026-0495(89)90176-5)
- Hill DJ & de Sousa D 1990 Insulin is a mitogen for isolated epiphyseal growth plate chondrocytes from the fetal lamb. *Endocrinology* **126** 2661–2670. (https://doi.org/10.1210/endo-126-5-2661)
- Hock JM, Centrella M & Canalis E 1988 Insulin-like growth factor I has independent effects on bone matrix formation and cell replication. *Endocrinology* 122 254–260. (https://doi.org/10.1210/endo-122-1-254)
- Irwin R, Lin HV, Motyl KJ & McCabe LR 2006 Normal bone density obtained in the absence of insulin receptor expression in bone. *Endocrinology* **147** 5760–5767. (https://doi.org/10.1210/en.2006-0700)
- Kovacs CS 2014 Bone development and mineral homeostasis in the fetus and neonate: roles of the calciotropic and phosphotropic hormones. *Physiological Reviews* **94** 1143–1218. (https://doi.org/10.1152/physrev.00014.2014)
- Lanham SA, Fowden AL, Roberts C, Cooper C, Oreffo ROC & Forhead AJ 2011a Effects of hypothyroidism on the structure and mechanical properties of bone in the ovine fetus. *Journal of Endocrinology* 210 189–198. (https://doi.org/10.1530/JOE-11-0138)
- Lanham SA, Bertram C, Cooper C & Oreffo ROC 2011b Animal models of maternal nutrition and altered offspring bone structure bone development across the lifecourse. *European Cells and Materials* 22 321–332; discussion 332. (https://doi.org/10.22203/ecm.v022a24)

- Liu JP, Baker J, Perkins AS, Robertson EJ & Efstratiadis A 1993 Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). *Cell* **75** 59–72. (https://doi.org/10.1016/S0092-8674(05)80084-4)
- Lok F, Owens JA, Mundy L, Robinson JS & Owens PC 1996 Insulin-like growth factor I promotes growth selectively in fetal sheep in late gestation. *American Journal of Physiology* **270** R1148–R1155. (https://doi.org/10.1152/ajpregu.1996.270.5.R1148)
- Philipps AF, Rosenkrantz TS, Clark RM, Knox I, Chaffin DG & Raye JR 1991 Effects of fetal insulin deficiency on growth in fetal lambs. *Diabetes* **40** 20–27. (https://doi.org/10.2337/diab.40.1.20)
- Pramojanee SN, Phimphilai M, Chattipakorn N & Chattipakorn SC 2014
 Possible roles of insulin signaling in osteoblasts. *Endocrine Research* **39**144–151. (https://doi.org/10.3109/07435800.2013.879168)
- Rios PDL & Hill DJ 2000 Expression and release of insulin-like growth factor binding proteins in isolated epiphyseal growth plate chondrocytes from the ovine fetus. *Journal of Cellular Physiology* **183** 172–181. (https://doi.org/10.1002/(SICI)1097-4652(200005)183:2<172::AID-JCP4>3.0.CO;2-S)
- Robinson PM, Comline RS, Fowden AL & Silver M 1983 Adrenal cortex of fetal lamb: changes after hypophysectomy and effects of Synacthen on cytoarchitecture and secretory activity. *Quarterly Journal of Experimental Physiology* 68 15–27. (https://doi.org/10.1113/expphysiol.1983.sp002697)
- Seref-Ferlengez Z, Suadicani SO & Thi MM 2016 A new perspective on mechanisms governing skeletal complications in type 1 diabetes. *Annals of the New York Academy of Sciences* **1383** 67–79. (https://doi.org/10.1111/nyas.13202)
- Sferruzzi-Perri AN, Vaughan OR, Forhead AJ & Fowden AL 2013 Hormonal and nutritional drivers of intrauterine growth. *Current Opinion* in Clinical Nutrition and Metabolic Care 16 298–309. (https://doi. org/10.1097/MCO.0b013e32835e3643)
- Yakar S, Werner H & Rosen CJ 2018 Insulin-like growth factors: actions on the skeleton. *Journal of Molecular Endocrinology* **61** T115–T137. (https://doi.org/10.1530/JME-17-0298)

Received in final form 23 October 2021 Accepted 27 October 2021 Accepted Manuscript published online 28 October 2021



© 2021 The authors

Printed in Great Britain

Published by Bioscientifica Ltd